Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments

Sang Bong Ahn

Clin Mol Hepatol. 2023;29(Suppl):S150-S156. Published online January 25, 2023

DOI: https://doi.org/10.3350/cmh.2022.0362

View: 2054 Download: 170 Citation: 1

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima

Clin Mol Hepatol. 2023;29(Suppl):S123-S135. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0357

View: 2394 Download: 161 Citations: 3

Editorial

The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B

Xianhua Mao, Lung Yi Mak, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(3):690-692. Published online May 30, 2023

DOI: https://doi.org/10.3350/cmh.2023.0173

View: 832 Download: 61

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Lynna Alnimer, Mazen Noureddin

Clin Mol Hepatol. 2023;29(2):394-397. Published online April 1, 2023

DOI: https://doi.org/10.3350/cmh.2023.0104

View: 1435 Download: 57

Original Article

Gut-derived lipopolysaccharide promotes alcoholic hepatosteatosis and subsequent hepatocellular carcinoma by stimulating neutrophil extracellular traps through toll-like receptor 4

Yang Liu, Xin Zhang, Shuo Chen, Jiazhong Wang, Shuo Yu, Yiming Li, Meng Xu, Harouna Aboubacar, Junhui Li, Tao Shan, Jixin Wang, Gang Cao

Clin Mol Hepatol. 2022;28(3):522-539. Published online May 4, 2022

DOI: https://doi.org/10.3350/cmh.2022.0039

View: 3564 Download: 153 Citations: 8

Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis

Gang Xu, Yu-Min Wang, Miao-Miao Ying, Sui-Dan Chen, Zong-Rui Li, Hong-Lei Ma, Ming-Hua Zheng, Jian Wu, Chunming Ding

Clin Mol Hepatol. 2021;27(2):329-345. Published online January 20, 2021

DOI: https://doi.org/10.3350/cmh.2020.0261

View: 5259 Download: 196 Citations: 13

Liver Imaging

Chemotherapy induced liver abnormalities: an imaging perspective

Ankush Sharma, Roozbeh Houshyar, Priya Bhosale, Joon-Il Choi, Rajesh Gulati, Chandana Lall

Clin Mol Hepatol. 2014;20(3):317-326. Published online September 25, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.3.317

View: 13625 Download: 286 Citations: 53

Review

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

The Korean Association for the Study of the Liver (KASL)

Clin Mol Hepatol. 2013;19(4):325-348. Published online December 28, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.4.325

View: 11920 Download: 153 Citations: 90

5

Fatty Liver

So Young Jin

Clin Mol Hepatol. 2006;12(1):112-115. Published online January 1, 1970

View: 2113 Download: 13

Original Article

Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity

Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe

Received January 30, 2023 Accepted July 5, 2023

DOI: https://doi.org/10.3350/cmh.2023.0035 [Epub ahead of print]

View: 914 Download: 117

Editorial

From NASH, MAFLD, to SLD: updates of nomenclature and impact on clinical trials

Ming-Lun Yeh, Ming-Lung Yu

Received September 15, 2023 Accepted September 18, 2023

DOI: https://doi.org/10.3350/cmh.2023.0359 [Accepted]

View: 65 Download: 11

1 |

Viewed By 7000	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 6129	A decade of liver organoids: Advances in disease modeling
Viewed By 3197	MAFLD: How is it different from NAFLD?
Viewed By 2745	Management of refractory ascites
Viewed By 2650	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 117	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Cited By 54	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 52	From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Cited By 46	Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Cited By 45	Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis

Search